219 related articles for article (PubMed ID: 31066619)
1. Preparation and characterization of novel albumin-sericin nanoparticles as siRNA delivery vehicle for laryngeal cancer treatment.
Yalcin E; Kara G; Celik E; Pinarli FA; Saylam G; Sucularli C; Ozturk S; Yilmaz E; Bayir O; Korkmaz MH; Denkbas EB
Prep Biochem Biotechnol; 2019; 49(7):659-670. PubMed ID: 31066619
[TBL] [Abstract][Full Text] [Related]
2. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
Liu P; Yu H; Sun Y; Zhu M; Duan Y
Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
[TBL] [Abstract][Full Text] [Related]
3. Glucose-linked sub-50-nm unimer polyion complex-assembled gold nanoparticles for targeted siRNA delivery to glucose transporter 1-overexpressing breast cancer stem-like cells.
Yi Y; Kim HJ; Zheng M; Mi P; Naito M; Kim BS; Min HS; Hayashi K; Perche F; Toh K; Liu X; Mochida Y; Kinoh H; Cabral H; Miyata K; Kataoka K
J Control Release; 2019 Feb; 295():268-277. PubMed ID: 30639386
[TBL] [Abstract][Full Text] [Related]
4. Designing siRNA-conjugated plant oil-based nanoparticles for gene silencing and cancer therapy.
Anilmis NM; Kara G; Kilicay E; Hazer B; Denkbas EB
J Microencapsul; 2019 Nov; 36(7):635-648. PubMed ID: 31509450
[TBL] [Abstract][Full Text] [Related]
5. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
[TBL] [Abstract][Full Text] [Related]
6. Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
Hatakeyama H; Wu SY; Mangala LS; Lopez-Berestein G; Sood AK
Methods Mol Biol; 2016; 1402():189-197. PubMed ID: 26721492
[TBL] [Abstract][Full Text] [Related]
7. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
Ding Y; Wang W; Feng M; Wang Y; Zhou J; Ding X; Zhou X; Liu C; Wang R; Zhang Q
Biomaterials; 2012 Dec; 33(34):8893-905. PubMed ID: 22979990
[TBL] [Abstract][Full Text] [Related]
8. Silica nanoparticles and polyethyleneimine (PEI)-mediated functionalization: a new method of PEI covalent attachment for siRNA delivery applications.
Buchman YK; Lellouche E; Zigdon S; Bechor M; Michaeli S; Lellouche JP
Bioconjug Chem; 2013 Dec; 24(12):2076-87. PubMed ID: 24180511
[TBL] [Abstract][Full Text] [Related]
9. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery.
Hartono SB; Gu W; Kleitz F; Liu J; He L; Middelberg AP; Yu C; Lu GQ; Qiao SZ
ACS Nano; 2012 Mar; 6(3):2104-17. PubMed ID: 22385282
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
11. Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA.
Liang J; Zhang X; He S; Miao Y; Wu N; Li J; Gan Y
J Control Release; 2018 Sep; 286():348-357. PubMed ID: 30077738
[TBL] [Abstract][Full Text] [Related]
12. Ultra-pH-Responsive and Tumor-Penetrating Nanoplatform for Targeted siRNA Delivery with Robust Anti-Cancer Efficacy.
Xu X; Wu J; Liu Y; Yu M; Zhao L; Zhu X; Bhasin S; Li Q; Ha E; Shi J; Farokhzad OC
Angew Chem Int Ed Engl; 2016 Jun; 55(25):7091-7094. PubMed ID: 27140428
[TBL] [Abstract][Full Text] [Related]
13. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
14. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
[TBL] [Abstract][Full Text] [Related]
15. Theranostic silk sericin/SPION nanoparticles for targeted delivery of ROR1 siRNA: Synthesis, characterization, diagnosis and anticancer effect on triple-negative breast cancer.
Shirangi A; Mottaghitalab F; Dinarvand S; Atyabi F
Int J Biol Macromol; 2022 Nov; 221():604-612. PubMed ID: 36084874
[TBL] [Abstract][Full Text] [Related]
16. Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery.
Cun D; Foged C; Yang M; Frøkjaer S; Nielsen HM
Int J Pharm; 2010 May; 390(1):70-5. PubMed ID: 19836438
[TBL] [Abstract][Full Text] [Related]
17. Nanoparticle-siRNA: a potential strategy for ovarian cancer therapy?
Aghamiri S; Mehrjardi KF; Shabani S; Keshavarz-Fathi M; Kargar S; Rezaei N
Nanomedicine (Lond); 2019 Aug; 14(15):2083-2100. PubMed ID: 31368405
[TBL] [Abstract][Full Text] [Related]
18. Enhanced endosomal escape by photothermal activation for improved small interfering RNA delivery and antitumor effect.
Yang X; Fan B; Gao W; Li L; Li T; Sun J; Peng X; Li X; Wang Z; Wang B; Zhang R; Xie J
Int J Nanomedicine; 2018; 13():4333-4344. PubMed ID: 30087564
[TBL] [Abstract][Full Text] [Related]
19. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
Yang X; Iyer AK; Singh A; Milane L; Choy E; Hornicek FJ; Amiji MM; Duan Z
Pharm Res; 2015 Jun; 32(6):2097-109. PubMed ID: 25515492
[TBL] [Abstract][Full Text] [Related]
20. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
